TVTX - Travere Therapeutics

...

Available for logged in users only.

The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.

• Travere Therapeutics expects FY22 revenue to be in line with consensus
• Travere Therapeutics GAAP EPS of -$1.09 misses by $0.17, revenue of $53.5M misses by $1.26M
• Travere Therapeutics Q3 2022 Earnings Preview
• Travere Therapeutics' FDA target action date for nephropathy treatment extended
• Travere, CSL kidney disease drug sparsentan gets review in EU
• Travere Therapeutics GAAP EPS of -$1.05 misses by $0.14, revenue of $54.2M beats by $4.7M
• Travere Theraspeutics a new buy at Canaccord as a 'rare disease powerhouse'
• Travere gains as FDA accepts marketing application for rare kidney disease therapy
• Travere Therapeutics falls 7% as analyst cuts price target
• Travere Therapeutics Non-GAAP EPS of $0.82 beats by $1.55, revenue of $48.5M misses by $3.42M
• Travere Therapeutics Q1 2022 Earnings Preview
• Travere Therapeutics CFO Laura Clague to retire
• Travere prices upsized $275M convertible senior notes offering
• Travere Therapeutics to raise $250M in senior notes offering
• Travere Therapeutics Non-GAAP EPS of -$0.61 misses by $0.11, revenue of $57.25M beats by $0.85M
• Travere Therapeutics Q4 2021 Earnings Preview
• Travere Therapeutics sees FY2021 revenue above consensus
• Travere Therapeutics gets new chief medical oficer
• Travere down 2% despite positive early-stage data for rare inherited disease therapy
• Travere Therapeutics EPS beats by $0.35, beats on revenue